Irisin-pretreated BMMSCs secrete exosomes to alleviate cardiomyocytes pyroptosis and oxidative stress to hypoxia/reoxygenation injury.

Jingyu Deng,Man Li,Taoyuan Zhang,Tao-Hong Hu,Hanwen Wei,Guang-wen Cao,Zheng Zhang
DOI: https://doi.org/10.2174/1574888X18666221117111829
2022-11-17
Current Stem Cell Research & Therapy
Abstract:BACKGROUND More effective strategies to improve myocardial ischemia/reperfusion (MI/R) injury is underdetermined. The cardiomyocytes pyroptosis and bone marrow-derived mesenchymal stem cells (BMMSCs) have been well considered as novel therapies to attenuate MI/R injury, however, the relationship has not yet been determined. OBJECTIVE We aims to clear whether pre-treatment BMMSCs to protect against MI/R injury by repressing cardiomyocytes pyroptosis, as well as to further elucidate the potential mechanisms. METHODS Cardiomyocytes were treated with hypoxia followed by reoxygenation to mimic MI/R injury. Pre-treatment BMMSCs or its exosomes were co-cultured with cardiomyocytes following to hypoxia/reoxygenation(H/R). Cell Counting Kit-8 (CCK-8) assay was used to determine cell viability. ROS production was determined by dihydroethidium (DHE) stain. Enzyme-linked immunosorbent assay (ELISA) were used to detect IL-1β and IL-18. RESULTS We indicated that Irisin pre-treatment BMMSCs (Irisin-BMMSCs) protected cardiomyocytes against hypoxia/reoxygenation(H/R)-induced injuries. The underlying molecular mechanism was further identified. Irisin-BMMSCs were found to secrete exosomes, which repressed cardiomyocytes pyroptosis and oxidative stress response by suppressing NLRP3 under H/R condition. CONCLUSION Based on our findings, we revealed a promising target that exosomes derived from BMMSCs with Irisin pre-treatment to elevate the therapeutic benefits for the H/R injury.
Medicine,Biology
What problem does this paper attempt to address?